LXRX
HealthcareLexicon Pharmaceuticals, Inc. · Biotechnology · $960M
What is Lexicon Pharmaceuticals, Inc.?
Lexicon Pharmaceuticals is a small-cap biopharmaceutical company focused on discovering and developing orally delivered small molecule drugs targeting serious conditions including heart failure and neuropathic pain.
Lexicon advances drug candidates through clinical trials and commercializes pharmaceutical products. Its pipeline includes Sotagliflozin, which completed Phase III trials for heart failure and type 1 diabetes, and LX9211, currently in Phase II development for neuropathic pain. The company also holds strategic collaboration and license agreements with Bristol-Myers Squibb and Genentech.
Incorporated in 1995 and headquartered in The Woodlands, Texas.
- Sotagliflozin – heart failure and type 1 diabetes treatment candidate
- LX9211 – Phase II neuropathic pain drug candidate
- Strategic licensing agreements with major pharmaceutical partners
Is LXRX a Good Stock to Buy?
UQS Score rates LXRX as Poor overall.
The Growth and Risk pillars stand out as relative bright spots within an otherwise challenged profile. The late-stage pipeline activity and partnership agreements provide some forward momentum.
Quality and Moat are both rated Weak, reflecting the early commercial stage and limited competitive durability. Valuation is rated Elevated, which adds caution for prospective investors.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LXRX pay dividends?
No — Lexicon Pharmaceuticals, Inc. does not currently pay a dividend.
Lexicon Pharmaceuticals does not currently pay a dividend. As a clinical-stage biopharma, the company reinvests available capital into research, development, and advancing its pipeline rather than returning cash to shareholders.
When does LXRX report earnings?
Lexicon Pharmaceuticals reports earnings on a quarterly cadence, typical for US-listed equities.
Results tend to reflect pipeline progress, operating expenses tied to clinical trials, and revenue from collaboration agreements rather than product sales at scale. Investors watch closely for clinical milestones alongside financial updates.
For the most recent quarter's results, see Lexicon Pharmaceuticals' investor relations page.
LXRX Price History
-58.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Lexicon Pharmaceuticals, Inc.?
Based on Lexicon Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Lexicon Pharmaceuticals do?
Lexicon Pharmaceuticals discovers, develops, and commercializes orally delivered small molecule drugs. Its lead programs target heart failure, type 1 diabetes, and neuropathic pain. The company also generates revenue through collaboration and licensing agreements with larger pharmaceutical partners.
Does LXRX pay dividends?
No, LXRX does not pay a dividend. Capital is directed toward clinical development and pipeline advancement, which is common for small-cap biopharmaceutical companies at this stage.
When does LXRX report earnings?
Lexicon Pharmaceuticals follows a standard quarterly reporting schedule. For confirmed dates and the latest results, visit the company's official investor relations page.
Is LXRX a good stock to buy?
UQS Score rates LXRX as Poor overall. While Growth and Risk show relative strength, Weak Quality and Moat ratings alongside an Elevated Valuation present meaningful concerns. The full pillar breakdown is available to Pro members.
Is LXRX overvalued?
The UQS Valuation pillar for LXRX is rated Elevated, suggesting the current price may not fully reflect the company's fundamental profile. Investors should weigh this against pipeline risk and the early commercial stage.
What is LXRX's market cap bracket?
LXRX is classified as a small-cap stock. Companies in this bracket typically carry higher volatility and risk relative to large- or mega-cap peers, though they can also offer greater upside if pipeline programs succeed.
Is LXRX a long-term quality indicator?
Based on UQS scoring, LXRX currently rates as Poor, with Weak Quality and Moat pillars limiting its long-term quality profile. Sustained improvement would likely require successful commercialization and stronger competitive positioning over time.
Who founded Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals was incorporated in 1995. Founding details are widely available through the company's public filings and official corporate history.
Unlock Full LXRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete pillar-by-pillar score breakdown for LXRX
- ✓Access full financial metrics and trend data
- ✓Compare LXRX against sector peers on every UQS dimension
- ✓Get the complete analyst view available to Pro members
Pro Analysis
LXRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 31.2 | 11.3 | 14.0 | 62.5 | 82.4 | 0.0 | +0.6 |
| Apr 2, 2026 | 30.6 | 11.3 | 14.0 | 62.5 | 78.5 | 0.0 | — |
LXRX — Pillar Breakdown
Quality
— 11.3/100 (25%)Lexicon Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.5/100 (20%)Lexicon Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Lexicon Pharmaceuticals, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Lexicon Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Lexicon Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LXRX.
Score Composition
Financial Data
More Stock Analysis
How is the LXRX UQS Score Calculated?
The UQS (Unified Quality Score) for Lexicon Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Lexicon Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Lexicon Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.